摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(3,5-Dichlorophenyl)-2-ethyltetrazole

中文名称
——
中文别名
——
英文名称
5-(3,5-Dichlorophenyl)-2-ethyltetrazole
英文别名
——
5-(3,5-Dichlorophenyl)-2-ethyltetrazole化学式
CAS
——
化学式
C9H8Cl2N4
mdl
——
分子量
243.09
InChiKey
BBXCLBFELFQYBE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    43.6
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    申请人:Sun Ying
    公开号:US20090035271A1
    公开(公告)日:2009-02-05
    The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
  • TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    申请人:Sun Ying
    公开号:US20090035268A1
    公开(公告)日:2009-02-05
    The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
  • US8785377B2
    申请人:——
    公开号:US8785377B2
    公开(公告)日:2014-07-22
查看更多